Tongce Medical Co., Ltd. Announcement on the Progress of Shareholding Increase by the Company's Directors, Senior Executives, and Other Management Personnel

MaticHoleFiller · 2026-03-29T02:07:54+00:00

Tongce Medical announces that the directors, senior management, and executives will increase their shareholdings. They plan to use their own funds to purchase a total of no less than 6 million yuan and no more than 12 million yuan starting from February 13, 2026. As of the announcement date, the chairman and others have already exceeded the minimum of the increase plan, with a total increase of tens of thousands of shares. The entities involved in the purchase will decide whether to continue increasing their holdings based on market conditions and have committed to complying with relevant laws and regulations.

MaticHoleFiller

2026-03-29 02:07:54

Abstract generation in progress

Security abbreviation: Tongce Medical Security code: 600763 No. Lin 2026-006

Tongce Medical Co., Ltd.

Announcement on the Progress of Share Acquisitions by the Company’s Directors, Senior Executives, and Other Management Personnel

The board of directors of the Company and all directors hereby guarantee that this announcement contains no false representations, misleading statements, or material omissions, and assume individual and joint liability for the truthfulness, accuracy, and completeness of the contents.

Key Points:

● Basic situation of the share acquisition plan: Tongce Medical Co., Ltd. (hereinafter referred to as “the Company”) has its chairwoman Wang Yi, director Huang Yuhua, the company’s secretary Zhang Hua, chief financial officer Xu Guoxi, and other management personnel Zhao Min plan to acquire shares of the Company through the Shanghai Stock Exchange’s system by centralized bidding using their own funds starting from February 13, 2026. The total transaction amount will be not less than RMB 6,000,000 and not more than RMB 12,000,000. No price range has been set for this acquisition.

● Progress of the share acquisition plan: As of the date of this announcement, Chairwoman Wang Yi has acquired 34,600 shares of the Company through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital; the acquisition amount has already exceeded the lower limit under the acquisition plan. Director Huang Yuhua has acquired 37,000 shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital; the acquisition amount has already exceeded the lower limit. Company Secretary Zhang Hua has acquired 34,700 shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital; the acquisition amount has already exceeded the lower limit. Chief Financial Officer Xu Guoxi has acquired 12,000 shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.003% of the Company’s total share capital; the acquisition amount has already exceeded the lower limit. Other management personnel Zhao Min has acquired 23,400 shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.005% of the Company’s total share capital; the acquisition amount has already exceeded the lower limit. Whether the acquisition counterparties will continue to acquire shares to reach the upper limit under the plan will depend on their own circumstances and the actual market conditions.

On February 14, 2026, the Company disclosed the “Announcement of Tongce Medical Co., Ltd. on the Acquisition of Shares by the Company’s Directors, Senior Executives, and Other Management Personnel and the Subsequent Share Acquisition Plan.” The Company now hereby announces the progress of share acquisitions by Chairwoman Wang Yi, Director Huang Yuhua, Company Secretary Zhang Hua, Chief Financial Officer Xu Guoxi, and Other management personnel Zhao Min as follows:

I. Basic information on the acquisition counterparties

(1) The acquisition counterparties in this round: Chairwoman Wang Yi, Director Huang Yuhua, Company Secretary Zhang Hua, Chief Financial Officer Xu Guoxi, and Other management personnel Zhao Min.

(2) As of the date of this announcement, Chairwoman Wang Yi directly holds 34,600 shares of the Company; Director Huang Yuhua directly holds 37,000 shares; Company Secretary Zhang Hua directly holds 34,700 shares; Chief Financial Officer Xu Guoxi directly holds 12,000 shares; Other management personnel Zhao Min directly holds 24,240 shares.

II. Main contents of this share acquisition plan

(1) Type of shares to be acquired: Tongce Medical (600763) A-share stock.

(2) Acquisition counterparties: Chairwoman Wang Yi, Director Huang Yuhua, Company Secretary Zhang Hua, Chief Financial Officer Xu Guoxi, and Other management personnel Zhao Min.

(3) Purpose of the share acquisition: Based on confidence in the Company’s continued and sustainable development in the future and recognition of the Company’s long-term investment value.

(4) Amount of shares to be acquired:

Chairwoman Wang Yi: not less than RMB 1,500,000, and not more than RMB 3,000,000.

Director Huang Yuhua: not less than RMB 1,500,000, and not more than RMB 3,000,000.

Company Secretary Zhang Hua: not less than RMB 1,500,000, and not more than RMB 3,000,000.

Chief Financial Officer Xu Guoxi: not less than RMB 500,000, and not more than RMB 1,000,000.

Other management personnel Zhao Min: not less than RMB 1,000,000, and not more than RMB 2,000,000.

Total: not less than RMB 6,000,000, and not more than RMB 12,000,000.

(5) Price of shares to be acquired: No price range has been set. The acquisition will be carried out based on a reasonable judgment of the value of the Company’s stock and, in accordance with the Company’s stock price fluctuations and the overall trend of the capital market, to implement the share acquisition plan.

(6) Under the premise that the acquisition complies with the provisions of the “Shanghai Stock Exchange Listing Rules” and relevant laws and regulations, as the counterparties continue to look favorably on the Company’s development prospects, the Company plans that within 6 months from the date of this share acquisition, if during the implementation period of the acquisition plan the Company’s stock is affected by circumstances such as planning major matters and a continuous suspension of trading of more than 10 trading days occurs, the acquisition period will correspondingly be extended.

(7) The acquisition counterparties will acquire shares of the Company directly through methods permitted by the Shanghai Stock Exchange trading system (including but not limited to block trading and centralized bidding) or through directed asset management plans or trust plans established by securities companies, fund management companies, trust companies, etc.

(8) Source of acquisition funds: own funds or self-raised funds.

III. Progress in the implementation of the share acquisition plan

As of the date of this announcement:

Chairwoman Wang Yi has acquired 34.6 thousand shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital, and the acquisition amount has already exceeded the lower limit under the acquisition plan;

Director Huang Yuhua has acquired 3.7 thousand shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital, and the acquisition amount has already exceeded the lower limit;

Company Secretary Zhang Hua has acquired 34.7 thousand shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.008% of the Company’s total share capital, and the acquisition amount has already exceeded the lower limit;

Chief Financial Officer Xu Guoxi has acquired 1.2 thousand shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.003% of the Company’s total share capital, and the acquisition amount has already exceeded the lower limit;

Other management personnel Zhao Min has acquired 2.34 thousand shares through the Shanghai Stock Exchange’s centralized bidding system, accounting for 0.005% of the Company’s total share capital, and the acquisition amount has already exceeded the lower limit.

IV. Uncertainty and risk in the implementation of the share acquisition plan

The implementation of this share acquisition plan may involve risks that the acquisition plan cannot meet expectations due to factors such as changes in the capital market situation. If any of the above risks occurs, the Company will timely fulfill its information disclosure obligations.

V. Other matters

The share acquisition conduct in this instance complies with relevant laws and regulations of the People’s Republic of China, departmental rules, Shanghai Stock Exchange business rules, and other related provisions.
The share acquisition conduct in this instance will not result in changes to the Company’s controlling shareholder and actual controller, nor will it lead to circumstances where the Company’s share distribution fails to meet listing conditions.
The acquisition counterparties in this instance will strictly comply with relevant laws and regulations, will not engage in insider trading or short-term trading, will not buy or sell the Company’s shares during the window period, and commit not to reduce holdings of the Company’s shares held during the implementation period of the acquisition plan and within statutory periods.
The Company will continue to monitor the progress of the acquisition of the Company’s shares by the acquisition counterparties. The information disclosure obligor will timely fulfill information disclosure obligations in accordance with relevant provisions such as the “Shanghai Stock Exchange Stock Listing Rules,” the “Measures for the Administration of the Acquisition of Listed Companies,” and the “Shanghai Stock Exchange Self-Regulatory Guidelines No. 8—Stock Change Management,” etc.

This announcement is hereby issued.

Board of Directors of Tongce Medical Co., Ltd.

March 28, 2026

Massive information, precise interpretation—available on the Sina Finance APP

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.